Showing posts with label daclatasvir (BMS-790052). Show all posts
Showing posts with label daclatasvir (BMS-790052). Show all posts

Monday, January 2, 2012

Bristol-Myers Squibb and Tibotec partner to evaluate daclatasvir-TMC435 combination for HCV




Bristol-Myers Squibb and Tibotec partner to evaluate daclatasvir-TMC435 combination for HCV: Bristol-Myers Squibb Company announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb's investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).